Surrozen (SRZN) Cash & Equivalents (2020 - 2026)
Surrozen (SRZN) posted quarterly Cash & Equivalents of $106.9 million for Q1 2026, up 5.18% year-over-year from $101.6 million in Q1 2025, and up 19.79% quarter-over-quarter from $89.2 million in Q4 2025.
Surrozen (SRZN) Cash & Equivalents (2020 - 2026) Analysis & Trends
Surrozen's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $106.9 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 5.18% year-over-year to $106.9 million; the TTM figure through Mar 2026 stood at $106.9 million (up 5.18% YoY), while the FY2025 annual figure was $89.2 million, up 158.19% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $106.9 million, up from $89.2 million in the prior quarter.
- The five-year high for Cash & Equivalents was $106.9 million in Q1 2026, with the low at $14.3 million in Q1 2022.
- The 5-year median for Cash & Equivalents is $34.6 million (2024), against an average of $48.0 million.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 58.21% in 2022, then soared 272.46% in 2025.
- Surrozen's Cash & Equivalents stood at $24.7 million in 2022, then soared by 45.98% to $36.0 million in 2023, then dropped by 4.1% to $34.6 million in 2024, then soared by 158.19% to $89.2 million in 2025, then gained by 19.79% to $106.9 million in 2026.
- Business Quant data shows SRZN's Cash & Equivalents at $106.9 million in Q1 2026, $89.2 million in Q4 2025, and $81.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 102.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.04 Mn |
| Mar 31, 2026 | 106.91 Mn |
| Dec 31, 2025 | 89.25 Mn |
| Sep 30, 2025 | 81.34 Mn |
| Jun 30, 2025 | 90.40 Mn |
| Mar 31, 2025 | 101.65 Mn |
| Dec 31, 2024 | 34.57 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Jun 30, 2024 | 37.77 Mn |
| Mar 31, 2024 | 27.29 Mn |
| Dec 31, 2023 | 36.04 Mn |
| Sep 30, 2023 | 33.98 Mn |
| Jun 30, 2023 | 36.50 Mn |
| Mar 31, 2023 | 27.81 Mn |
| Dec 31, 2022 | 24.69 Mn |
| Sep 30, 2022 | 25.53 Mn |
| Jun 30, 2022 | 16.87 Mn |
| Mar 31, 2022 | 14.31 Mn |
| Dec 31, 2021 | 33.09 Mn |
| Sep 30, 2021 | 61.10 Mn |